APO Research
Talk to an analyst

APO RESEARCH · REPORT

5 Nucleotidase

5 Nucleotidase refers to research coverage of agents targeting 5-prime nucleotidase/CD73 within the selected edition.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The selected edition names investigational agents rather than bulk enzyme supply. Target identity, agent, development stage and study scope are distinct; inclusion is not evidence of approval or treatment efficacy.

What turns activity into demand

Distinguish equipment procurement, recurring materials and any related service within the selected study. Research use, educational use and clinical use have different acceptance requirements and should not be treated as one demand measure.

The commercial boundary

Separate research materials, devices and services within the selected edition. Approvals, labelled use and clinical acceptance need their own evidence; no medical suitability follows from this illustration.

Which supplied scope and interfaces define 5 Nucleotidase?

The selected edition names investigational agents rather than bulk enzyme supply. Target identity, agent, development stage and study scope are distinct; inclusion is not evidence of approval or treatment efficacy.

Technical reading

Selected research

Market Outlook & Growth Opportunities

Global 5 Nucleotidase Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry Research5 Nucleotidase Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal 5 Nucleotidase Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal 5 Nucleotidase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 5 Nucleotidase Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal 5 Nucleotidase Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global 5 Nucleotidase market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for 5 Nucleotidase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the 5 Nucleotidase market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the 5 Nucleotidase market include Bristol-Myers Squibb Co, Corvus Pharmaceuticals Inc, Innate Pharma SA, MedImmune LLC and Surface Oncology Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global 5 Nucleotidase market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of 5 Nucleotidase and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents 5 Nucleotidase sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the 5 Nucleotidase market size, projected growth trends, production technologies, key applications, and end-use industries.

5 Nucleotidase Segment by Company

Bristol-Myers Squibb Co

Corvus Pharmaceuticals Inc

Innate Pharma SA

MedImmune LLC

Surface Oncology Inc

5 Nucleotidase Segment by Type

IPH-53

CPX-006

BMS-986179

AB-680

Others

5 Nucleotidase Segment by Application

Colorectal Cancer

Fallopian Tube Cancer

Gastric Cancer

Metastatic Colorectal Cancer

Others

5 Nucleotidase Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global 5 Nucleotidase status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions 5 Nucleotidase market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify 5 Nucleotidase significant trends, drivers, influence factors in global and regions.

6. To analyze 5 Nucleotidase competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 5 Nucleotidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 5 Nucleotidase and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 5 Nucleotidase.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the 5 Nucleotidase market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global 5 Nucleotidase industry.

Chapter 3: Detailed analysis of 5 Nucleotidase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of 5 Nucleotidase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of 5 Nucleotidase in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. 5 Nucleotidase Industry Trends Table 2. 5 Nucleotidase Industry Drivers Table 3. 5 Nucleotidase Industry Opportunities and Challenges Table 4. 5 Nucleotidase Industry Restraints Table 5. Global 5 Nucleotidase Revenue by Company (US$ Million) & (2021-2026) Table 6. Global 5 Nucleotidase Revenue Share by Company (2021-2026) Table 7. Global 5 Nucleotidase Sales Volume by Company (W Units) & (2021-2026) Table 8. Global 5 Nucleotidase Sales Volume Share by Company (2021-2026) Table 9. Global 5 Nucleotidase Average Price (US$/Unit) of Company (2021-2026) Table 10. Global 5 Nucleotidase Company Ranking, (2024-2026) & (USD Million) Table 11. Global 5 Nucleotidase Key Company Manufacturing Base & Headquarters Table 12. Global 5 Nucleotidase Company, Product Type & Application Table 13. Global 5 Nucleotidase Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global 5 Nucleotidase by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of IPH-53 Table 18. Significant Companies of CPX-006 Table 19. Significant Companies of BMS-986179 Table 20. Significant Companies of AB-680 Table 21. Significant Companies of Others Table 22. Global 5 Nucleotidase Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global 5 Nucleotidase Sales Volume by Type (2021-2026) & (W Units) Table 24. Global 5 Nucleotidase Sales Volume by Type (2027-2032) & (W Units) Table 25. Global 5 Nucleotidase Sales Volume Share by Type (2021-2026) Table 26. Global 5 Nucleotidase Sales Volume Share by Type (2027-2032) Table 27. Global 5 Nucleotidase Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global 5 Nucleotidase Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global 5 Nucleotidase Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global 5 Nucleotidase Sales Value Share by Type (2021-2026) Table 31. Global 5 Nucleotidase Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Colorectal Cancer Table 33. Significant Companies of Fallopian Tube Cancer Table 34. Significant Companies of Gastric Cancer Table 35. Significant Companies of Metastatic Colorectal Cancer Table 36. Significant Companies of Others Table 37. Global 5 Nucleotidase Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global 5 Nucleotidase Sales Volume by Application (2021-2026) & (W Units) Table 39. Global 5 Nucleotidase Sales Volume by Application (2027-2032) & (W Units) Table 40. Global 5 Nucleotidase Sales Volume Share by Application (2021-2026) Table 41. Global 5 Nucleotidase Sales Volume Share by Application (2027-2032) Table 42. Global 5 Nucleotidase Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global 5 Nucleotidase Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global 5 Nucleotidase Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global 5 Nucleotidase Sales Value Share by Application (2021-2026) Table 46. Global 5 Nucleotidase Sales Value Share by Application (2027-2032) Table 47. Global 5 Nucleotidase Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global 5 Nucleotidase Sales by Region (2021-2026) & (W Units) Table 49. Global 5 Nucleotidase Sales Market Share by Region (2021-2026) Table 50. Global 5 Nucleotidase Sales by Region (2027-2032) & (W Units) Table 51. Global 5 Nucleotidase Sales Market Share by Region (2027-2032) Table 52. Global 5 Nucleotidase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global 5 Nucleotidase Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global 5 Nucleotidase Sales Value Share by Region (2021-2026) Table 55. Global 5 Nucleotidase Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global 5 Nucleotidase Sales Value Share by Region (2027-2032) Table 57. Global 5 Nucleotidase Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global 5 Nucleotidase Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global 5 Nucleotidase Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global 5 Nucleotidase Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global 5 Nucleotidase Sales by Country (2021-2026) & (W Units) Table 62. Global 5 Nucleotidase Sales Market Share by Country (2021-2026) Table 63. Global 5 Nucleotidase Sales by Country (2027-2032) & (W Units) Table 64. Global 5 Nucleotidase Sales Market Share by Country (2027-2032) Table 65. Global 5 Nucleotidase Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global 5 Nucleotidase Sales Value Market Share by Country (2021-2026) Table 67. Global 5 Nucleotidase Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global 5 Nucleotidase Sales Value Market Share by Country (2027-2032) Table 69. Bristol-Myers Squibb Co Company Information Table 70. Bristol-Myers Squibb Co Business Overview Table 71. Bristol-Myers Squibb Co 5 Nucleotidase Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bristol-Myers Squibb Co 5 Nucleotidase Product Portfolio Table 73. Bristol-Myers Squibb Co Recent Development Table 74. Corvus Pharmaceuticals Inc Company Information Table 75. Corvus Pharmaceuticals Inc Business Overview Table 76. Corvus Pharmaceuticals Inc 5 Nucleotidase Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Corvus Pharmaceuticals Inc 5 Nucleotidase Product Portfolio Table 78. Corvus Pharmaceuticals Inc Recent Development Table 79. Innate Pharma SA Company Information Table 80. Innate Pharma SA Business Overview Table 81. Innate Pharma SA 5 Nucleotidase Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Innate Pharma SA 5 Nucleotidase Product Portfolio Table 83. Innate Pharma SA Recent Development Table 84. MedImmune LLC Company Information Table 85. MedImmune LLC Business Overview Table 86. MedImmune LLC 5 Nucleotidase Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. MedImmune LLC 5 Nucleotidase Product Portfolio Table 88. MedImmune LLC Recent Development Table 89. Surface Oncology Inc Company Information Table 90. Surface Oncology Inc Business Overview Table 91. Surface Oncology Inc 5 Nucleotidase Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Surface Oncology Inc 5 Nucleotidase Product Portfolio Table 93. Surface Oncology Inc Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. 5 Nucleotidase Distributors List Table 97. 5 Nucleotidase Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. 5 Nucleotidase Product Image Figure 2. Global 5 Nucleotidase Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 5 Nucleotidase Sales Value (2021-2032) & (US$ Million) Figure 4. Global 5 Nucleotidase Sales (2021-2032) & (W Units) Figure 5. Global 5 Nucleotidase Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global 5 Nucleotidase Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. IPH-53 Image Figure 10. CPX-006 Image Figure 11. BMS-986179 Image Figure 12. AB-680 Image Figure 13. Others Image Figure 14. Global 5 Nucleotidase Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global 5 Nucleotidase Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global 5 Nucleotidase Sales Volume Share by Type (2021-2032) Figure 17. Global 5 Nucleotidase Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global 5 Nucleotidase Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global 5 Nucleotidase Sales Value Share by Type (2021-2032) Figure 20. Colorectal Cancer Image Figure 21. Fallopian Tube Cancer Image Figure 22. Gastric Cancer Image Figure 23. Metastatic Colorectal Cancer Image Figure 24. Others Image Figure 25. Global 5 Nucleotidase Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global 5 Nucleotidase Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global 5 Nucleotidase Sales Volume Share by Application (2021-2032) Figure 28. Global 5 Nucleotidase Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global 5 Nucleotidase Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global 5 Nucleotidase Sales Value Share by Application (2021-2032) Figure 31. Global 5 Nucleotidase Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global 5 Nucleotidase Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global 5 Nucleotidase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global 5 Nucleotidase Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America 5 Nucleotidase Sales Value (2021-2032) & (US$ Million) Figure 36. North America 5 Nucleotidase Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe 5 Nucleotidase Sales Value (2021-2032) & (US$ Million) Figure 38. Europe 5 Nucleotidase Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific 5 Nucleotidase Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific 5 Nucleotidase Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America 5 Nucleotidase Sales Value (2021-2032) & (US$ Million) Figure 42. South America 5 Nucleotidase Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa 5 Nucleotidase Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa 5 Nucleotidase Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt 5 Nucleotidase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. 5 Nucleotidase Value Chain Figure 130. Manufacturing Cost Structure Figure 131. 5 Nucleotidase Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • IPH-53
  • CPX-006
  • BMS-986179
  • AB-680
  • Others
Applications
  • Colorectal Cancer
  • Fallopian Tube Cancer
  • Gastric Cancer
  • Metastatic Colorectal Cancer
  • Others
Companies covered
  • Bristol-Myers Squibb Co
  • Corvus Pharmaceuticals Inc
  • Innate Pharma SA
  • MedImmune LLC
  • Surface Oncology Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global 5 Nucleotidase Sales Value (2021-2032)
  4. 1.2.2 Global 5 Nucleotidase Sales Volume (2021-2032)
  5. 1.2.3 Global 5 Nucleotidase Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 5 Nucleotidase Market Dynamics
  1. 2.1 5 Nucleotidase Industry Trends
  2. 2.2 5 Nucleotidase Industry Drivers
  3. 2.3 5 Nucleotidase Industry Opportunities and Challenges
  4. 2.4 5 Nucleotidase Industry Restraints
3 5 Nucleotidase Market by Company
  1. 3.1 Global 5 Nucleotidase Company Revenue Ranking in 2025
  2. 3.2 Global 5 Nucleotidase Revenue by Company (2021-2026)
  3. 3.3 Global 5 Nucleotidase Sales Volume by Company (2021-2026)
  4. 3.4 Global 5 Nucleotidase Average Price by Company (2021-2026)
  5. 3.5 Global 5 Nucleotidase Company Ranking (2024-2026)
  6. 3.6 Global 5 Nucleotidase Company Manufacturing Base and Headquarters
  7. 3.7 Global 5 Nucleotidase Company Product Type and Application
  8. 3.8 Global 5 Nucleotidase Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global 5 Nucleotidase Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 5 Nucleotidase Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 5 Nucleotidase Market by Type
  1. 4.1 5 Nucleotidase Type Introduction
  2. 4.1.1 IPH-53
  3. 4.1.2 CPX-006
  4. 4.1.3 BMS-986179
  5. 4.1.4 AB-680
  6. 4.1.5 Others
  7. 4.2 Global 5 Nucleotidase Sales Volume by Type
  8. 4.2.1 Global 5 Nucleotidase Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global 5 Nucleotidase Sales Volume by Type (2021-2032)
  10. 4.2.3 Global 5 Nucleotidase Sales Volume Share by Type (2021-2032)
  11. 4.3 Global 5 Nucleotidase Sales Value by Type
  12. 4.3.1 Global 5 Nucleotidase Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global 5 Nucleotidase Sales Value by Type (2021-2032)
  14. 4.3.3 Global 5 Nucleotidase Sales Value Share by Type (2021-2032)
5 5 Nucleotidase Market by Application
  1. 5.1 5 Nucleotidase Application Introduction
  2. 5.1.1 Colorectal Cancer
  3. 5.1.2 Fallopian Tube Cancer
  4. 5.1.3 Gastric Cancer
  5. 5.1.4 Metastatic Colorectal Cancer
  6. 5.1.5 Others
  7. 5.2 Global 5 Nucleotidase Sales Volume by Application
  8. 5.2.1 Global 5 Nucleotidase Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global 5 Nucleotidase Sales Volume by Application (2021-2032)
  10. 5.2.3 Global 5 Nucleotidase Sales Volume Share by Application (2021-2032)
  11. 5.3 Global 5 Nucleotidase Sales Value by Application
  12. 5.3.1 Global 5 Nucleotidase Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global 5 Nucleotidase Sales Value by Application (2021-2032)
  14. 5.3.3 Global 5 Nucleotidase Sales Value Share by Application (2021-2032)
6 5 Nucleotidase Regional Sales and Value Analysis
  1. 6.1 Global 5 Nucleotidase Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global 5 Nucleotidase Sales by Region (2021-2032)
  3. 6.2.1 Global 5 Nucleotidase Sales by Region: 2021-2026
  4. 6.2.2 Global 5 Nucleotidase Sales by Region (2027-2032)
  5. 6.3 Global 5 Nucleotidase Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global 5 Nucleotidase Sales Value by Region (2021-2032)
  7. 6.4.1 Global 5 Nucleotidase Sales Value by Region: 2021-2026
  8. 6.4.2 Global 5 Nucleotidase Sales Value by Region (2027-2032)
  9. 6.5 Global 5 Nucleotidase Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America 5 Nucleotidase Sales Value (2021-2032)
  12. 6.6.2 North America 5 Nucleotidase Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe 5 Nucleotidase Sales Value (2021-2032)
  15. 6.7.2 Europe 5 Nucleotidase Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific 5 Nucleotidase Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific 5 Nucleotidase Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America 5 Nucleotidase Sales Value (2021-2032)
  21. 6.9.2 South America 5 Nucleotidase Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa 5 Nucleotidase Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa 5 Nucleotidase Sales Value Share by Country, 2025 VS 2032
7 5 Nucleotidase Country-level Sales and Value Analysis
  1. 7.1 Global 5 Nucleotidase Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global 5 Nucleotidase Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global 5 Nucleotidase Sales by Country (2021-2032)
  4. 7.3.1 Global 5 Nucleotidase Sales by Country (2021-2026)
  5. 7.3.2 Global 5 Nucleotidase Sales by Country (2027-2032)
  6. 7.4 Global 5 Nucleotidase Sales Value by Country (2021-2032)
  7. 7.4.1 Global 5 Nucleotidase Sales Value by Country (2021-2026)
  8. 7.4.2 Global 5 Nucleotidase Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt 5 Nucleotidase Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt 5 Nucleotidase Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt 5 Nucleotidase Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb Co
  2. 8.1.1 Bristol-Myers Squibb Co Company Information
  3. 8.1.2 Bristol-Myers Squibb Co Business Overview
  4. 8.1.3 Bristol-Myers Squibb Co 5 Nucleotidase Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Co 5 Nucleotidase Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Co Recent Developments
  7. 8.2 Corvus Pharmaceuticals Inc
  8. 8.2.1 Corvus Pharmaceuticals Inc Company Information
  9. 8.2.2 Corvus Pharmaceuticals Inc Business Overview
  10. 8.2.3 Corvus Pharmaceuticals Inc 5 Nucleotidase Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Corvus Pharmaceuticals Inc 5 Nucleotidase Product Portfolio
  12. 8.2.5 Corvus Pharmaceuticals Inc Recent Developments
  13. 8.3 Innate Pharma SA
  14. 8.3.1 Innate Pharma SA Company Information
  15. 8.3.2 Innate Pharma SA Business Overview
  16. 8.3.3 Innate Pharma SA 5 Nucleotidase Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Innate Pharma SA 5 Nucleotidase Product Portfolio
  18. 8.3.5 Innate Pharma SA Recent Developments
  19. 8.4 MedImmune LLC
  20. 8.4.1 MedImmune LLC Company Information
  21. 8.4.2 MedImmune LLC Business Overview
  22. 8.4.3 MedImmune LLC 5 Nucleotidase Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MedImmune LLC 5 Nucleotidase Product Portfolio
  24. 8.4.5 MedImmune LLC Recent Developments
  25. 8.5 Surface Oncology Inc
  26. 8.5.1 Surface Oncology Inc Company Information
  27. 8.5.2 Surface Oncology Inc Business Overview
  28. 8.5.3 Surface Oncology Inc 5 Nucleotidase Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Surface Oncology Inc 5 Nucleotidase Product Portfolio
  30. 8.5.5 Surface Oncology Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 5 Nucleotidase Value Chain Analysis
  2. 9.1.1 5 Nucleotidase Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 5 Nucleotidase Sales Mode & Process
  6. 9.2 5 Nucleotidase Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 5 Nucleotidase Distributors
  9. 9.2.3 5 Nucleotidase Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst